Folic acid supplementation improves erythropoietin response

Area of Science:

• Nephrology
• Hematology
• Nutritional Science

Background:

• Recombinant human erythropoietin (rhEPO) is crucial for treating anemia in chronic kidney disease patients.
• Impaired responsiveness to rhEPO therapy is a clinical challenge in some patients.
• The impact of rhEPO on folic acid metabolism in renal anemia was previously unclear.

Purpose of the Study:

• To investigate the effect of rhEPO therapy on folic acid metabolism in patients with chronic renal disease.
• To determine if folic acid supplementation impacts rhEPO efficacy and patient hematocrit levels.
• To assess the relationship between rhEPO treatment and folic acid requirements.

Main Methods:

• A cohort of 13 patients with chronic renal diseases and impaired rhEPO responsiveness was studied.
• Mean corpuscular volume (MCV) and hematocrit (Hct) were monitored before and during rhEPO therapy.
• Folic acid was administered additionally to assess its effect on hematological parameters and rhEPO response.

Main Results:

• rhEPO therapy led to a significant increase in MCV, indicating developing macrocytic anemia.
• Folic acid supplementation effectively overcame the macrocytic anemia and normalized MCV.
• Hematocrit levels significantly improved with the addition of folic acid, despite normal baseline folic acid serum levels.

Conclusions:

• rhEPO therapy increases the body's demand for folic acid, irrespective of baseline serum levels.
• Folic acid administration enhances rhEPO therapy's effectiveness in improving hematocrit in renal anemia patients.
• Supplementing folic acid can potentially allow for a reduction in rhEPO dosage.